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LIST OF ABBREVIATIONS 
AMPA: α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid,  
BBB: blood-brain barrier,  
BDNF: brain-derived nerve growth factor, 
cCBF: cortical cerebral blood flow, 
EAA: extracellular amino acid, 
fEPSPs: field excitatory postsynaptic potentials,  
FJ-B: Fluoro Jade B, 
FJ+: Fluoro Jade positive 
GABA: gamma-aminobutyric acid 
Glu: glutamate, 
Gly: glycine, 
HFS: high-frequency stimulation,  
HR: heart rate, 
IDO: indolamine 2,3-dioxygenase,  
IO curves: input-output curves, 
KYN: kynurenine,  
KYNA: kynurenic acid, 
MABP: mean arterial blood pressure,  
L-NAME: nitro-L-arginine methyl ester,  
LTP: long-term potentiation, 
NA: noradrenaline, 
NeuN: anti-neuronal nuclei, 
NMDA: N-methyl-D-aspartate,  
NO: nitric oxide,  
NOS: nitric oxide synthase, 
PSD: post-stroke depression, 
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PROB: probenecid,  
QUIN: quinolinic acid,  
SC: sham control, 
SSRI: selective serotonin reuptake inhibitor,  
TRP: tryptophan, 




Kynurenine pathway. Kynurenic acid – a glutamate antagonist. 
Rationale of therapeutic administration of  kynurenic acid in 
certain experimental conditions. Pathomechanism of depression 
also involves glutamate hyperactivity.   
Kynurenine (KYN) is a central material of the major route 
for tryptophan (TRP) metabolism. KYN can be metabolized in two 
separate ways: one branch results in the formation of kynurenic acid 
(KYNA), while the other leads to quinolinic acid (QUIN), the 
precursor of NAD. KYNA is the only known endogenous excitatory 
amino acid (EAA) receptor blockers with a broad spectrum of 
antagonistic properties in supraphysiological concentrations. On the 
other hand, QUIN is a specific agonist at the NMDA receptors, and a 
potent neurotoxin with an additional marked free radical-producing 
property.  
Summary: QUIN may result in excitotoxic neuronal cell death, while 
in stark contrast, the other KYN pathway metabolite, KYNA, 
protects neurons. There are some diseases where elevations of QUIN 
in the brain have been implicated, e.g. CNS inflammation, stroke, 
traumatic brain injury, epilepsy, malignant gliomas, neuropathic pain 
and certain neurodegenerative disorders. In these states, 
hyperactivity of glutamate (Glu) receptors in certain areas of the 
brain occurs, causing excitotoxic cell death. On the other hand, in 
diseases with cognitive alterations, such as Alzheimer’s type 
dementia and schizophrenia, elevated levels of brain KYNA have 
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been demonstrated, which could contribute to cognitive defects by 
influencing NMDA receptors. Pharmacological manipulations of Glu 
receptors can hold promise for the amelioration of some dramatic 
consequences of excitotoxicy. KYNA can be a candidate for it. 
However, the use of KYNA itself as a neuroprotective agent can be 
difficult because it hardly crosses the blood brain barrier (BBB), 
whereas L-KYN is easily transported across it. Accordingly, the 
systemic administration of L- KYN dose-dependently elevates the 
level of KYNA in the brain.  
The pathomechanism of depression is also supposed to involve 
Glu receptor hyperactivity in the cortico-limbic (hippocampal) 
pathways. Key role of chronic stress followed by hyperactivity of the 
glucocorticoid axis in its pathomechanism is unaequivocal. 
“Vascular depression” is related to various types of cerebrovascular 
lesions in the cortex or subcortical white matter. The lesions are 
believed to interrupt cortico-subcortical (cortico-limbic and cortico-
striatal) pathways which can cause biochemical changes, leading to 
alterations in mood (rather than the localized structural damage 
itself). Vascular depression and “idiosyncratic” depression can share 
some common features in their pathomechanism. The role of chronic 
peripheral immune activation and subsequent release of 
proinflammatory cytokines by macrophages and dendritic cells in the 
brain, and hence chronic low-grade cerebral inflammation has come 
into focus in recent years. Cytokines in the brain can further 
stimulate the hypothalamo-pituitary-adrenal axis, disturb 
monoaminergic neurotransmission, and induce the enzyme 
indolamine 2,3-dioxygenase (IDO). This enzyme initiates the 
catabolism of TRP through the KYN pathway. Heightened TRP 
catabolism in the KYN pathway toward the QUIN arm was reported. 
An imbalance between the two arms of the pathway can exert an 
impact on the Glu-ergic neurotransmission in the brain. It has been 
suggested that impaired neuroprotection may play an important role 
in the pathophysiology and treatment resistance of depression. 
Theoretically, pharmacological inhibition of Glu receptors in 




Our own studies – our purposes 
1. To investigate whether peripheral L-KYN administration has 
any neuroprotective effect on hippocampal cell survival under 
global ischemic conditions in the brain. 
In our study, we evaluated the effect of L-KYN administration (300 
mg/kg i.p.) on the hippocampus of the global ischemic (transiently 
four-vessel occluded: 4VO) rat brain, administering the L-KYN 
before and after the ischemic insult. We used the rat 4VO model, 
mimicking global ischemia, which is a widely recognized model in 
ischemic studies.  
2. How does peripheral L-KYN loading influence the 
physiological long-term potentiation (LTP) in the ischemic rat 
hippocampus?  
We investigated how KYN (300 mg/kg) treatment influences LTP in 
the hippocampus in the rat 4VO model. Global ischemia is known to 
elicit selective, delayed neuronal death. The pyramidal neurons of 
hippocampal CA1 area are particularly vulnerable. Activity-
dependent LTP, a model of synaptic plasticity, also mediated by Glu 
receptors, may likewise be impaired by global ischemia. This too 
was addressed in our experiments.  
3. Do small doses of peripherally administered L-KYN influence 
the cortical CBF (cCBF) under normal and chronic ischemic 
conditions of the brain in the rabbit? 
As little amount of information is available on the effects of the 
KYN system on the CBF, we investigated the effects of low doses 
(0.3, 1 and 3 mg/kg) of L-KYN on the cCBF under normal and 
ischemic conditions of the brain in awake rabbits.  
4. Do the antidepressant drugs citalopram and fluoxetine have 
any effects on the cCBF in normal rabbits and in animals with 
CBF impairement induced by chronic unilateral carotid 
occlusion? 
Antidepressants have proved to be partly effective in vascular 
depression, but little was eatlier known about their in vivo vascular 
effects. We investigated for the first time the effects of two selective 
SER reuptake inhibitor antidepressant drugs (SSRIs), citalopram and 
fluoxetine, on the normal and the carotid ligation-induced ischemic 
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cCBF, and also on the mean arterial blood pressure (MABP) and the 
heart rate (HR) in awake rabbits. 
EXPERIMENT 1 
KYNURENINE DIMINISHES THE ISCHEMIA-INDUCED 
HISTOLOGICAL AND ELECTROPHYSIOLOGICAL 
DEFICITS IN THE RAT HIPPOCAMPUS 
The aim of our study was to reveal whether KYN can rescue the 
CA1 neurons in the 4VO model in the rat. KYN was administered 
together with PROB, an organic acid transporter inhibitor, in order to 
facilitate the brain penetration of KYN.  
 
Materials and methods 
Animals 
Adult male Wistar rats (n = 43, 280-300 g) were used. 
Four-vessel occlusion and drug treatment 
The rats were anesthetized with Nembutal (60 mg/kg, i.p.). Both 
vertebral arteries were occluded by cauterization. On the following 
day, the animals were subjected to 10-min forebrain ischemia by 
bilateral occlusion of the carotid arteries with atraumatic clips under 
ether anesthesia. Both vertebral arteries were cauterized, and both 
common carotid arteries were exposed, but not occluded in the sham-
operated animals. 
The rats used for histology were divided into 4 groups: sham-
operated controls (SC group, n = 5), 4VO animals (4VO group, n = 
7), KYN+PROB-pretreated animals (KYN+PROB-4VO group, n = 
6) and KYN+PROB-post-treated animals (4VO-KYN+PROB 
group, n = 7). 
The rats used for electrophysiology were divided into 3 groups: 
sham-operated controls (SC group, n = 6), 4VO animals (4VO 
group, n = 6) and KYN+PROB-pretreated animals (KYN+PROB-
4VO group, n = 6).  
KYN (300 mg/kg, i.p.) and PROB (200 mg/kg, i.p.) were 
administered daily for 5 days: in the pretreated group, the first 
KYN+PROB administration preceded the 10-min carotid occlusion 
by 2 h; then the animals were treated at the same time on the next 4 
days. In the post-treated group, the animals received the first 
KYN+PROB injection at the start of reperfusion. The remaining 4 
injections were given at the same time on the next 4 days. 
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Histological procedures 
Ten days after 4VO, the rats were anesthetized with urethane (2.2 
g/kg, i.p.), and perfused transcardially with 0.1 M phosphate-
buffered saline, and then with 4% paraformaldehyde. The 
brains were removed from the cranium, post-fixed in formalin, 
cryopreserved in 20% sucrose and sectioned at 32 m with a 
cryostat microtome. The degenerating cells were stained with 
Fluoro Jade B®, while that of viable cells were identified by anti-
neuronal nuclei (NeuN) immunohistochemistry. The locations of FJ-
B positive (FJ+) cells were observed with a fluorescence microscope 
(viewed at 4x magnification and the most dorsal part of CA1 was 
counted at 20x magnification) and fluorescence photomicrographs 
were obtained.  
The labeled cells were calculated for 1 mm2. The numbers of FJ+ 
and NeuN-immunopositive neurons/mm2 were determined in each 
slide of all animals. 
In vitro electrophysiology 
The electrophysiological recordings were conducted 10 days after 
4VO. The rats (n =3x6) were decapitated, and coronal slices (400 
m) were prepared from the middle part of their hippocampi with a 
vibratome. The slices were then transferred into a Haas-type 
recording chamber and incubated. The stimulating electrode was 
placed in the stratum radiatum near the border of the CA3 region to 
perform orthodromic stimulation of the Schaffer collateral/ 
commissural pathway.  
Field excitatory postsynaptic potentials (fEPSPs) were recorded 
in parallel from the stratum radiatum. The test stimulus intensity was 
adjusted to the 30-60 A range to evoke approximately 50% of the 
maximal stimulus intensity that evoked maximal fEPSP response in 
the SC rats. LTP of the Schaffer collateral-CA1 synaptic response 
was induced by high-frequency stimulation (HFS) (0.2-ms pulses 
delivered at 100 Hz for 6 s), then the fEPSPs were recorded for a 
further period of at least 60 min. Input-output (IO) curves were 
created to measure the basal Glu-ergic synaptic function.  
HPLC-MS/MS analysis of KYN and KYNA levels in the plasma 
and brain tissue 
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The vertebral arteries were occluded 24 h before treatments with 
vehicle or KYN and PROB. Two hours later, the rats were 
anesthetized with pentobarbital (60 mg/kg i.p.). No bilateral carotid 
artery occlusion was performed. Blood was taken from the aorta, and 
centrifuged. After decapitation, tissue samples were obtained from 
the hippocampus and cerebral cortex, and weighed. The plasma and 
brain tissue was stored at about -70 oC until analysis. Upon 
thawing, the brain tissue was homogenized in a potter. The 
HPLC-MS/MS system was used to measure the KYN and KYNA 
content of the samples. 
Statistical analysis 
Neuronal cell counts are presented as means ± SEM, and were 
analyzed by using one-way ANOVA followed by the Bonferroni test 
for multiple.comparisons. A p  0.05 was considered significant. A 
nonparametric test on two independent samples was chosen for 
electrophysiological data (Mann-Whitney U-test). 
Results 
Histology 
In animals subjected to 10-min 4VO, severe neuronal damage 
was observed in the CA1 area of the hippocampus in both 
hemispheres 10 days after the intervention. In this injured region, 
numerous of the pyramidal cells in the CA1 region were FJ+ in each 
of the coronal sections, while those in the CA3 region and the 
dentate gyrus were not labeled.  
In accordance with this, the NeuN immunohistochemistry 
indicated a lack of intact cells in the CA1 region in the 4VO animals, 
but an intact CA3 region and dentate gyrus. 
KYN administration 
KYN (300 mg/kg, i.p.) administered together with PROB (200 
mg/kg, i.p.) caused a marked reduction in the number of damaged 
neurons. In the KYN-pretreated animals, injured neurons stained 
with FJ-B could be observed only sporadically in the CA1 area of the 
hippocampus (the same was true for the CA3 region and the dentate 
gyrus).  
Accordingly, NeuN immunohistochemistry gave the impression 
of a non-injured CA1 region (like the CA3 region and the dentate 
gyrus) in KYN-pretreated 4VO animals. 
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KYN administration considerably decreased the number of 
injured neurons in the CA1 region. However, the decrease in the 
number of injured neurons was highly significant only in the 
pretreated group. The animals in the post-treated group also 
exhibited a tendency to a reduction in the number of injured neurons, 
but this change was not significant. The NeuN 
immunohistochemistry supplemented these results: the number of 
non-injured cells was highest in the SC group, and lowest in the 4VO 
animals. Post-treatment with KYN had minimal effect, while in the 
4VO animals which received KYN before ischemia the number of 
intact cells was comparable to the control level.  
We also investigated the change in the numbers of injured cells in 
the cortex. We obtained similar results, i.e. a significant 
neuroprotective effect of L-KYN treatment. The only difference was 
that post-treatment also proved to be significant in the cortex. In 
short, the KYN+PROB pretreatment was able to reduce the 
proportion of damaged cells to 52% relative to the damaged cells 
induced by 4VO without KYN+PROB treatment. The KYN+PROB 
treatment after the 4VO intervention did not prove to be effective in 
the hippocampus. 
In vitro electrophysiology 
The input-output (IO) curves of SC, 4VO and 4VO animals which 
received KYN+PROB treatment were established by plotting the 
fEPSP amplitudes against various test pulse intensities from 0 to 100 
A. No significant difference was found between the IO curves in 
the three groups, implying that the basal functions of the pyramidal 
cells and synapses were not affected by complete ischemia. 
LTP was induced by HFS of the Schaffer collateral-CA1 
synapses. In the SC group, the HFS caused a robust increase (170-
180%) in the slope of the fEPSPs and this increase in slope (and in 
amplitude) remained at the elevated level during the 1-h registration 
period. The same conditioning protocol did not induce a significant, 
lasting increase of the fEPSPs in the majority of the 4VO animals. In 
this group, the elevation of the amplitudes was only transient; no 
LTP was observed. At the end of the registration period, the slopes 
had returned to the control level, or decreased below the baseline. 
The administration of KYN and PROB protected slices from the 
4VO-induced LTP impairment. KYN restored the fEPSP slopes to 
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the control level, and these parameters were stable until 60 min after 
HFS. 
Plasma and brain KYN and KYNA concentrations 
Treatment with KYN+PROB considerably increased both the 
KYN and KYNA concentrations in the plasma and brain, and also 
altered their proportions within the compartments studied, but this 
was probably due to the relatively large scatter of the data. In the 
sham-operated rats, KYN concentration was approximately 3-fold 
higher in the plasma than in the cortex and hippocampus. On the 
other hand, the KYNA concentration was higher in the cortex and 
hippocampus than in the plasma (p < 0.001), and higher in the cortex 
than in the hippocampus. The KYN concentration increased 37-fold 
in the plasma and approximately 70-fold in the hippocampus and 
cortex, while the KYNA concentration was elevated roughly 300-
fold in the plasma and 50-fold in the hippocampus and cortex.  
 
EXPERIMENT 2 
EFFECTS OF SYSEMIC ADMINISTRATION OF L-KYN ON 
THE CORTICOCEREBRAL BLOOD FLOW UNDER 
NORMAL AND ISCHEMIC CONDITIONS OF THE BRAIN 
IN AWAKE RABBITS 
The aim of the present study was to examine whether peripherally 
administered L-KYN can influence the normal and the unilateral 
carotid artery occlusion induced ischemic cCBF in awake rabbits. 
Materials and Methods 
Animals 
Altogether 60 New-Zealand white rabbits weighing 2.5-3 kg were 
used 
Surgical preparation 
Introduction of electrodes into the cerebral cortex. Rabbits were 
anesthetized with an intravenous solution of diazepam (20 mg/kg) 
and ketamine (20 mg/kg) in physiological saline solution. Six 
hydrogen-sensitive electrodes, consisting of glass-insulated (O.D. 0.5 
mm) platinum wire (diameter 0.1 mm) with a bare tip length of 1 mm, 
were inserted stereotaxically into the parietal cortex. After a 3-5-day 
recovery period, the animals were in good physical condition. 
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Occlusion of the carotid artery. In the ischemic group of animals, 
permanent surgical occlusion was accomplished with ligatures on the 
left external and internal carotid arteries. The operation was 
performed under the same general anesthesia as above.  
Measurements 
Measurement of cCBF. The rabbits were allowed to recover for 3 
days after surgery, and the cCBF was determined at 6 sites in their 
brain by means of the hydrogen clearance technique. The basal and 
the unilateral carotid occlusion-induced impaired cCBF, and the flow 
changes following drug treatment were determined. One of the 
groups consisting of 6 awake rabbits without drug treatment was 
used to measure the effect of physiological saline solution as control, 
on the cCBF.  
Measurement of MABP, HR and blood gas parameters. The 
MABP was measured in conscious rabbits via a catheter inserted into 
the left or right central ear artery, connected through a pressure 
transducer, at the same time, the ECG was continuously recorded by 
a radiotelemetry system in order to monitor the HR. Arterial pH, 
pCO2, pO2 and O2 saturation were measured at intervals, utilizing a 
blood gas analyzer. 
Drug treatment 
The marginal ear vein was cannulated and used for the 
administration of L-KYN and other agents.  
L-KYN free base was freshly dissolved in physiological saline 
solution each day and was administered intravenously in a volume of 
1.5-2 ml. First the baseline values were registered, and then the 
effects of L-KYN on the cCBF, MABP and HR were followed for 
240 min. 
As vasodilation in the cerebral vessels can be mediated via 
acethylcholine and/or nitric oxide (NO), we gave their selective 
inhibitors to investigate the potential mechanisms of L-KYN on 
cerebral vessels.  
 Atropine sulfate (1 mg/kg) was given intravenously in aqueous 
solution in a volume of 2-3 ml 5 min before the administration of L-
KYN (1 mg/kg), and the cCBF, MABP and HR values and the L-
KYN-induced responses were registered. 
 Nitro-L-arginine methyl ester (L-NAME) (40 mg/kg) was 
administered intravenously in aqueous solution in a volume of 1 ml 
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after registration of the basal cCBF values. Thereafter, the 
measurements were repeated; 45 min later L-KYN (1 mg/kg) was 
administered and the changes in cCBF, MABP and HR were 
determined. 
Statistical analysis 
The results were expressed as means ± SEM. Data were collected 
in pairs from the same measuring sites (electrodes) before and after 
the experimental intervention or the administration of agents. The 
statistical significance of the observed differences was calculated by 
Student’s paired t-test and repeated measures analysis of variance 
(ANOVA). Multiple comparison of different time points and groups 
was carried out by means of one-way ANOVA. p values < 0.05, 
when obtained with both statistical tests, were considered significant. 
Significance of reductions in mean basal cCBF values in the 
controls and in animals with unilateral carotid occlusions treated 
with 0.3, 1 and 3 mg/kg L-KYN (Group “1”, “2” and “3”) were 
calculated by means of the unpaired Student’s t-test. p values < 0.05 
were considered significant. 
Results 
 Administration of L-KYN resulted in a significant increase in the 
normal cCBF. This effect was particularly obvious after the 
administration of 1 mg/kg L-KYN. The cCBF was enhanced by all 
three applied doses of L-KYN within 30 min, attained its maximum 
values soon thereafter, and remained high even around the 240th min, 
i.e. at the end of the recording period. 
Treatment with physiological saline solution did not change the 
cCBF significantly.  
 Unilateral carotid occlusion caused a significant reduction in 
cCBF from 117±15 to 57±11 (“1”), from 90±12 to 52±8 (“2”) and 
from 113±10 to 58±11 (“3”) ml/min/100 g tissue.  
 Following the administration of L-KYN, there was an immediate 
increase in the cCBF in the animals with carotid occlusion. The 
L-KYN-induced maximal percentage increases in the cCBF in the 
ischemic animals were more pronounced than the cCBF decreases 
caused by unilateral occlusion (92-94% /at 1 mg/kg dose/ vs 42-
51%). This effect was of long duration, and peak values were 
recorded at 60-240 min after L-KYN injection. 
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 Pretreatment with atropine or L-NAME prevented the cCBF-
increasing effect of 1 mg/kg L-KYN in the control rabbits and also in 
those with carotid occlusion. 
 L-KYN did not alter the MABP or HR, whereas L-NAME caused 
a small increase in the MABP as did atropine in the HR. The 
duration of the latter effects was relatively short (< 60 min).  
 No significant changes in the arterial blood gas parameters or pH 




EFFECTS OF CITALOPRAM AND FLUOXETINE ON THE 
CORTICOCEREBRAL BLOOD FLOW IN AWAKE RABBITS 
In our study, we investigated for the first time the effects of two 
SSRI antidepressants, citalopram and fluoxetine, on the normal and 
the carotid ligation-induced ischemic cCBF, and also on MABP and 
HR in awake rabbits.  
Materials and Methods 
Male and female New Zealand White rabbits (altogether n=64) 
weighing 2.5-3.0 kg were used.  
Surgical preparation  
 Introduction of electrodes into the cerebral cortex, occlusion of 
the carotid artery: This was performed on the same way as described 
in Experiment 2.  
Measurements 
 Measurement of cCBF, MABP and HR: This was also the same as 
described previously.  
Drug treatment 
The marginal ear vein was cannulated and used for the 
administration of drugs, which were freshly dissolved in 
physiological saline solution each day. The effects of each of the 
individual doses (0.1, 0.3 and 1.0 mg/kg) of fluoxetine or citalopram 
were investigated separately and each animal was treated with only 
one dose of drug. The amounts of drugs applied in the study 
correspond to the therapeutically meaningful (antidepressant) human 
doses. 
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Fluoxetine was administered intravenously as a bolus, in a total 
volume of 1 ml. 
Citalopram hydrochloride was infused continuously for 60 min 
(total volume 10 ml).  
The basal and the unilateral carotid occlusion-induced impaired 
cCBF and the cCBF changes following fluoxetine or citalopram 
treatment were determined at 10 min and every 30 min during 150 
min after drug administration.  
Statistical analysis 
The results were expressed as means ± SEM. Student,s paired 
t-test and for multiple comparisons of different time points and 
groups one-way ANOVA were used. Only p values < 0.05 with both 
statistical tests were considered significant. 
Results 
Fluoxetine and citalopram caused only minor, insignificant 
changes in the normal cCBF. Unilateral carotid occlusion produced a 
significant decrease in cCBF in all 6 control groups (90±1748±16; 
88±1649±14; 87±1441±16) and 92±1848±17; 
97±1456±15; 98±1655±17 ml/min/100g tissue). Fluoxetine did 
not influence the cCBF significantly at any dose in the ischemic 
animals; there was only a very slight tendency to an increase. In 
contrast, citalopram (0.1, 0.3 or 1 mg/kg in infusion) improved the 
unilateral carotid occlusion-induced impaired cCBF response as 
compared with the basal occluded values. The effect was dose-
dependent; the most pronounced change was seen in response to 1 
mg/kg citalopram, i.e. the highest applied dose of this drug. The 
average maximal changes were: 48±1758±19, 56±1572±19 and 
55±1782±21 ml/min/100g tissue at 0.1, 0.3 and 1.0 mg/kg 
citalopram, respectively. 
The cCBF-increasing effects appeared toward the end of the 150-
min recording period: the peak values were obtained at 90-120 min.  
Administration of 10 ml physiological saline solution did not alter 
the cCBF significantly in either the control or the ischemic group. 
Both fluoxetine and citalopram decreased the HR as compared 
with the baseline value. Fluoxetine administration caused a slight, 
but significant dose-dependent reduction in HR in both the normal 
and the ischemic group. At the highest dose (i.e. 1 mg/kg), the HR 
was reduced by 13-14%. The treatment with citalopram affected the 
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HR significantly only at the 0.3 and 1 mg/kg doses of the drug, and 
the percentage changes were lower relative to those observed after 
fluoxetine administration (3-5%).  
No significant changes in MABP were noted in the fluoxetine-
treated groups. However, significant reductions in MABP were 
observed in the groups treated with 0.3 or 1 mg/kg citalopram under 





SUMMARY AND CONCLUSIONS 
L-KYN (300 mg/kg) + PROB (200 mg/kg) i.p. pretreatment 
caused significant neuroprotection in a global ischemic rat model, 
while its effect as post-treatment was moderate. L-KYN (0.1, 1 and 3 
mg/kg i.v.) led to an increase in cCBF in both the control rabbits and 
the animals with chronic cerebral ischemia induced by chronic 
unilateral carotid artery occlusion. While the hippocampal neuron 
rescue effect of L-KYN could be due to the Glu antagonistic 
property of its immediate derivative, the mechanism of its cCBF-
enhancing effect remains to be elucidated. Involvement of the 
cholinergic pathways of the cranial parasympathetic nervous system 
could be assumed, in which vasodilation is related to the release of 
NO, as atropine, an anticholinergic drug, or L-NAME, a NOS 
inhibitory drug, attenuated the cCBF-increasing effect. In any case, 
this effect could have an additional beneficial impact on the disease 
outcome under ischemic conditions in the brain.  
In another study, we investigated whether the SSRI drugs 
fluoxetine and citalopram (0.1, 0.3 and 1 mg/kg) influence the cCBF 
in doses corresponding to that used in clinical settings. We found that 
only citalopram had a significant effect on the cCBF: it improved the 
unilateral carotid occlusion-induced impaired cCBF response. 
Besides the possibility of the blocking of Ca2+ and/or Na+ channels 
on cerebral arteries by SSRI drugs, several authors have proposed 
that these drugs can exert a secondary (inhibitory) action on the Glu - 
NMDA receptors in addition to their primary inhibitory action at the 
SER transporter. Taken together, the cation channel-inhibitory or 
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NMDA receptor antagonistic properties of citalopram may have 
played a role in the beneficial effect of the drug in the animals with 
an impaired cCBF induced by unilateral carotid occlusion in our 
experiments. Both fluoxetine and citalopram slightly decreased the 
HR, whereas higher doses of citalopram reduced the MABP under 
either normal or unilateral carotid occlusion-induced ischemic 
conditions. However, it is not likely that the mild alterations in the 
peripheral circulatory parameters could efficiently influence the 
cCBF. On the basis of our findings, citalopram may have advantages 
in the treatment of PSD and other types of vascular depression, but 
further studies of the exact mechanism by which the drug improves 
the cCBF are clearly necessary. 
Details of our results can be itemized as follows: 
1. In our 4VO rat ischemia model, there was severe neuronal damage 
in the CA1 area of the hippocampus in both hemispheres 10 days 
after the intervention, as proved by FJ-B staining and NeuN 
immunohistochemistry. The CA3 area and the dentate gyrus 
remained intact. KYN (300 mg/kg, i.p.) administered together with 
PROB (200 mg/kg, i.p.) considerably decreased the number of 
injured neurons in the CA1 region. However, the decrease in the 
number of injured neurons was highly significant only in the 
pretreated group (to 52% relative to the damaged cells induced by 
4VO without KYN+PROB treatment). The animals in the post-
treated group also exhibited a tendency to a reduction in the number 
of injured neurons, but this change was not significant. The NeuN 
immunohistochemistry results were in accord with those observed 
with FJ-B staining: in the 4VO model, post-treatment with KYN had 
hardly any effect, while KYN pretreatment proved to be highly 
neuroprotective: the number of intact cells was comparable to the 
control level. 
2. Our in vitro electrophysiological studies indicated that in 4VO rats, 
there was no significant difference between the IO curves in the three 
groups, implying that the basal functions of the registered pyramidal 
cells and synapses were not affected by complete ischemia. In the 
majority of the 4VO animals, no LTP was observed. The 
administration of KYN and PROB protected the brain slices from the 
4VO-induced LTP impairment. KYN restored the fEPSP slopes to 
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the control level, and these parameters were stable until 60 min after 
HFS. 
3. Administration of KYN (300 mg/kg) + PROB (200 mg/kg) to 
4VO rats considerably increased both the KYN and KYNA 
concentrations in the plasma and brain, and also altered their 
proportions within the brain compartments studied. The KYN 
concentration increased 37-fold in the plasma and approximately 70-
fold in the hippocampus and cortex, while the KYNA concentration 
was elevated roughly 300-fold in the plasma and 50-fold in the 
hippocampus and cortex.  
4. Chronic unilateral carotid occlusion caused a significant reduction 
in cCBF in awake rabbits (from 117±15 to 57±11 (“1”), from 90±12 
to 52±8 (“2”) and from 113±10 to 58±11 (“3”) ml/min/100 g tissue ). 
L-KYN administered intravenously in single doses of 0.3, 1 and 3 
mg/kg resulted in a significant increase in the cCBF in the control 
rabbits, and also in the animals with unilateral carotid occlusion. The 
effect was particularly obvious after the administration of 1 mg/kg L-
KYN.  
5. Pretreatment with atropine (1 mg/kg) or L-NAME (40 mg/kg) 
prevented the cCBF-increasing effect of 1 mg/kg L-KYN in control 
rabbits and also in those with chronic unilateral carotid occlusion. 
6. Both SSRI drugs fluoxetine and citalopram (in individual doses of 
0.1, 0.3 and 1.0 mg/kg, which correspond to the therapeutic human 
doses) caused only minor, insignificant changes in the normal cCBF 
in rabbits.  
7. Citalopram (0.1, 0.3 or 1 mg/kg in infusion) improved the 
unilateral carotid occlusion-induced impaired cCBF response as 
compared with the basal occluded values. The effect was dose-
dependent; the most pronounced change was seen in response to 1 
mg/kg citalopram, i.e. the highest applied dose of the drug. 
8. Both fluoxetine and citalopram decreased the HR as compared 
with the baseline value.  
9. Significant reductions in MABP were observed in the groups 
treated with 0.3 or 1 mg/kg citalopram under either normal or 
unilateral carotid occlusion-induced ischemic conditions.  
 
KYNA-like agents – as potential antiglutamatergic drugs for the 
future 
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Glu is a predominant excitatory transmitter in the central 
nervous system. Glu-ergic neurotransmission plays an important role 
in many physiological processes, such as learning, development of 
the nervous system, moving, sensation and mood control. Under 
particular circumstances, its extreme release may cause irreversible 
damage to the neurons through their overexcitation. This is termed 
excitotoxicity and is involved in the pathogenesis of many diseases 
which are apparently different in nature (stroke, neurodegenerative 
and mood disorders, etc.). In these cases, a therapeutic elevation of 
the brain KYNA content may hold promise to diminish the 
consequences of excitotoxicity. On the other hand, it must be 
mentioned that in diseases with cognitive alterations, such as 
Alzheimer’s dementia and schizophrenia, elevated brain KYNA 
levels have been reported which could contribute to the cognitive 
defects by interfering with the NMDA receptor function. 
Our experiments demonstrated that KYN treatment abates 
neuronal cell loss in a rat global ischemia model, in the pathogenesis 
of which excitotoxicity is assumed. In addition, low doses of L-KYN 
enhance the cCBF in rabbits under both normal and ischemic 
conditions of the brain. Citalopram, an SSRI drug, increased the 
cCBF only in rabbits with unilateral carotid occlusion. Its precise 
mechanism is still unclear, but an NMDA antagonistic effect of the 
drug may be involved. Our findings strengthen the data which 
indicate that KYNA or one of its derivatives with better 
bioavailability may be fruitful in the treatment of certain acute or 
chronic neurological diseases involving Glu receptor hyperactivity in 
their pathomechanism. 
POTENTIAL CLINICAL RELEVANCE OF THE RESULTS 
The pathological overactivation of Glu receptors plays a role 
in the pathogenesis of numerous neurological and psychiatric 
diseases. Abatement of the excitotoxic process can retard the disease 
course and diminish its damaging consequences. 
In our experiments, L-KYN, an NMDA receptor antagonist 
prodrug that is produced within the body, proved to be 
neuroprotective in a transient global ischemic animal model. 
Although NMDA receptor antagonists failed in most acute stroke 
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trials, as they suspend even the physiological NMDA receptor 
function and thereby cause severe side-effects, smaller doses of L-
KYN administered for a longer period of time may theoretically halt 
the neurodegenerative process, and (as this is an endogenous 
substance) may lack toxic side-effects. 
In the event of therapeutic administration, the additional CBF-
increasing effect of L-KYN under chronic cerebral ischemic 
conditions may provide further benefit. 
Hyperactivity of the NMDA receptors in the cortico-
hippocampal pathways in depression may be presumed, a precise 
understanding of which may hold further therapeutic perspectives. 
Citalopram, an SSRI antidepressant drug, dose-dependently 
increased the CBF in animals, a feature in favor of its use in PSD. 
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